Legend Biotech Corp Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019
Legend Biotech Corp (LEGN) reported Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019 of $19.04 per share for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-10.
Financial Statements › Notes › Compensation Related Costs
ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 · last filed 2026-03-10
| Period end | Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019 12 month |
|---|---|
| 2025-12-31 | $19.04 20-F · filed 2026-03-10 |
| 2024-12-31 | $31.41 20-F · filed 2026-03-10 |
| 2023-12-31 | $23.53 20-F · filed 2026-03-10 |
| 2022-12-31 | $19.45 20-F · filed 2025-03-11 |
| 2021-12-31 | $15.48 20-F · filed 2024-03-19 |
| 2020-12-31 | $15.61 20-F · filed 2023-03-30 |
| 2019-12-31 | $1.50 20-F/A · filed 2023-02-17 |
| 2018-12-31 | $1.00 20-F · filed 2021-04-02 |